Zucara Therapeutics Inc.
PrivateLast Round
Series B
May 1, 2025
Total Funding Raised
$52.76M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Zucara Therapeutics Inc. operates in Healthcare & Life Sciences and is based in Toronto. Its latest recorded funding round was a Series B round in May 2025.
Zucara Therapeutics Inc. is a biotechnology company developing ZT-01, a first-in-class, once-daily therapeutic to prevent hypoglycemia in people with Type 1 and other insulin-dependent types of diabetes.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Zucara Therapeutics Inc. Comparables
Compare Zucara Therapeutics Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Abvance Therapeutics | 76% | |
| vTv Therapeutics Inc | 75% | |
| Zealand Pharma | 72% |
For institutional investors. Book with your work email.
Zucara Therapeutics Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 1, 2025 | ||||
| Grant | Jun 15, 2023 | ||||
| Grant | May 2, 2022 | ||||
| Grant | Nov 2, 2020 | ||||
| Series A | Mar 31, 2020 | ||||
Grant | Jul 12, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Zucara Therapeutics Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Canadian Glycomics Network | Grant |
| Perceptive Advisors | Series B, Series A |
| Helmsley Charitable Trust | Debt |
| National Research Council Canada Industrial Research Assistance Program | Grant |
| Mitacs | Grant |
| JDRF | Series B, Grant |
| TIAP | Accelerator |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 109% MoM, reaching 1.7K.
- Nov 7, 2025
Monthly visitors increased 88% MoM.
For institutional investors. Book with your work email.
Zucara Therapeutics Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Zucara Therapeutics Inc.'s valuation, stock price, and market status.
Is Zucara Therapeutics Inc. a public or private company?
Zucara Therapeutics Inc. is a private company.
What is the current stock price of Zucara Therapeutics Inc.?
Zucara Therapeutics Inc. is a private company, so its shares have no public market price. Caplight tracks Zucara Therapeutics Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Zucara Therapeutics Inc. worth (valuation)?
Valuation information for Zucara Therapeutics Inc. is not publicly available.
Can I buy Zucara Therapeutics Inc. stock?
Zucara Therapeutics Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Zucara Therapeutics Inc.'s last funding round?
Zucara Therapeutics Inc.'s most recent funding round was Series B on May 1, 2025.
Who are the main investors in Zucara Therapeutics Inc.?
Key investors in Zucara Therapeutics Inc. include Perceptive Advisors, Helmsley Charitable Trust.
Will Zucara Therapeutics Inc. IPO soon?
No public IPO plans have been announced for Zucara Therapeutics Inc..
How can I track Zucara Therapeutics Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Zucara Therapeutics Inc.'s shares on secondary markets.